Prednisone
- Generic Name
- Prednisone
- Brand Names
- Deltasone, Rayos, Winpred
- Drug Type
- Small Molecule
- Chemical Formula
- C21H26O5
- CAS Number
- 53-03-2
- Unique Ingredient Identifier
- VB0R961HZT
- Background
A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.
Prednisone was granted FDA approval on 21 February 1955.
- Indication
Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.
- Associated Conditions
- Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis
- Associated Therapies
- Palliative Treatment
ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- Ambrx, Inc.
- Target Recruit Count
- 352
- Registration Number
- NCT04662580
- Locations
- 🇺🇸
The Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸UCSF, San Francisco, California, United States
🇺🇸Urology Cancer Center, XCancer Research Network, Omaha, Nebraska, United States
A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT04660799
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun City, China
🇨🇳Peking University Third Hospital, Beijing, China
🇨🇳Fujian Provincial Cancer Hospital, Fuzhou City, China
Belimumab Treatment for IgG4-related Disease
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2021-01-08
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04660565
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Study to Evaluate the Efficacy of Immunosuppression in Myocarditis or Inflammatory Cardiomyopathy.
- First Posted Date
- 2020-12-04
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Medical University of Warsaw
- Target Recruit Count
- 100
- Registration Number
- NCT04654988
- Locations
- 🇵🇱
First Department of Cardiology, Medical University of Warsaw, Warsaw, Poland
Corticosteroids in Community Acquired Pneumonia
- Conditions
- Interventions
- First Posted Date
- 2020-12-03
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Vanderbilt University Medical Center
- Registration Number
- NCT04652414
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-11-18
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 86
- Registration Number
- NCT04633252
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Study of CC-90011 and Comparators in Participants With Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Celgene
- Target Recruit Count
- 6
- Registration Number
- NCT04628988
- Locations
- 🇺🇸
Local Institution - 101, New York, New York, United States
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
- First Posted Date
- 2020-11-13
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Academic and Community Cancer Research United
- Target Recruit Count
- 45
- Registration Number
- NCT04626791
- Locations
- 🇺🇸
Ochsner NCI Community Oncology Research Program, New Orleans, Louisiana, United States
🇺🇸Aurora Cancer Care-Milwaukee West, Wauwatosa, Wisconsin, United States
🇺🇸Mount Sinai Hospital, New York, New York, United States
A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)
- Conditions
- Interventions
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- argenx
- Target Recruit Count
- 222
- Registration Number
- NCT04598451
- Locations
- 🇬🇧
Investigator site 117 - UK0440021, Birmingham, United Kingdom
🇧🇬Investigator site 30 - BG350012, Pleven, Bulgaria
🇧🇬Investigator site 31 - BG3590013, Plovdiv, Bulgaria
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)
- Conditions
- Interventions
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- argenx
- Target Recruit Count
- 183
- Registration Number
- NCT04598477
- Locations
- 🇺🇸
Investigator site 124 - US0010092, Redwood City, California, United States
🇺🇸Investigator site 1 - US0010087, Boca Raton, Florida, United States
🇺🇸Investigator site 91 - US0010109, Orlando, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.